Roxilab 500 mg
Generic : Cefuroxime Axetil
Therapeutic : Cefuroxime Axetil
Composition :
Roxilab 250 Tablet: Each film coated tablet contains Cefuroxime 250 mg as Cefuroxime Axetil BP.
Roxilab 500 Tablet: Each film coated tablet contains Cefuroxime 500 mg as Cefuroxime Axetil BP.
Roxilab Powder for Suspension: Each 5 ml reconstituted suspension contains 125 mg Cefuroxime as Cefuroxime Axetil BP.
Description :
Cefuroxime is one of the bactericidal second generation cephalosporin antibiotics which is active against a wide range of Gram-positive and Gram-negative susceptible organisms including many beta-lactamase producing strains.
Indications :
Cefuroxime is indicated in the treatment of:
Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. Acute bacterial otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains), Moraxella catarrhalis (including beta-lactamase producing strains) or Streptococcus
pyogenes.
Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase producing strains only).
Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains).
Uncomplicated skin and skin-structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes. Uncomplicated urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae.
Uncomplicated gonorrhoea (urethral and endocervical) caused by penicillinase-producing and non-penicillinase producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhoea, rectal, in females, caused by non-penicillinase producing strains of Neisseria gonorrhoeae. Impetigo caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes.
Dosage and Administration :
Cefuroxime Tablets:
Cefuroxime Suspension:
Side effects :
Cefuroxime has been associated with nausea, vomiting, headache, rashes, dizziness in a small number of patients.
Use in special group :
Pregnancy: There is no experimental evidence of embryopathic or teratogenic effect attributable to Cefuroxime but as with all medicines, it should be administered with caution during the early months of pregnancy.
Nursing mother: Cefuroxime is excreted in human milk and consequently, caution should be exercised when Cefuroxime Axetil is administered to a nursing mother.
Pediatric use: The safety and effectiveness of Cefuroxime have been established for pediatric patient aged 3 months to 12 years for acute bacterial maxillary sinusitis based upon its approval in adults.
Contraindications :
Cefuroxime is contraindicated in patients with known allergy to cephalosporins.
Precautions :
Prolonged use of Cefuroxime may result in the over growth of non-susceptible organisms (e.g. Candida, Enterococci, Clostridium difficile), which may result interruption of treatment.
Drug Interaction :
No potentially hazardous interaction have been reported. In common with other antibiotics, Cefuroxime Axetil may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral contraceptives.
Storage :
Store in a cool and dry place, away from light. Keep out of the reach of children.
Commercial Pack :
Roxilab 250 Tablet: Each box contains 2 x 7 tablets in Alu-Alu blister pack.
Roxilab 500 Tablet: Each box contains 1 x 7 tablets in Alu-Alu blister pack.
Roxilab Powder for Suspension: Each bottle contains Cefuroxime powder for
preparation of 70 ml suspension.
Download Product Manual
Back